- MRNA shares slump on Tuesday after a strong bounce on Monday.
- FXStreet had called the Monday bounce as likely to fail.
- Moderna needs to find a new revenue source as covid likely to fade.
Moderna (MRNA) shares failed to rally on Tuesday despite Fed Chair Powell talking calmly to Capitol Hill and soothing most equities in the process. Risk was back on and rate hikes are also likely on, this time in March. Powell has carefully mapped out the strategy so as not to surprise markets, and despite yields rising slightly, tech continued to bounce on Tuesday. However, Moderna shares slumped.
Moderna (MRNA) stock news
Shares in Moderna closed over 5% lower at $221.39 on Tuesday. Many traders are asking why, when all major indices closed higher. Mainstream media have been trotting out the rotation line, which is a neat excuse for, "We don't really know why that happened, so let us just compare it to something else."
The fact as always is to do with momentum and trends. Moderna has been falling, and this latest fall is symptomatic of waning investor interest as covid looks to fade. Moderna is hugely over-reliant on its covid vaccine for income. Yes, it has a decent pipeline, but nothing else can come close to matching the revenue generation of its covid vaccine. This is the big problem.
Pfizer is much more diversified and a larger company with multiple revenue streams. Moderna (MRNA) is not in this league. It may get there one day, but in the meantime it will face revenue generation challenges. Take a look at the Moderna development pipeline here. It is impressive but nothing that looks either imminent or significant in terms of replacing covid vaccine revenue. Covid is/was a once-in-a-century event (fingers crossed).
Moderna (MRNA) stock forecast
There is nothing significant in Monday's move despite MRNA shares closing 9% higher. We outlined this in our article earlier in the week and remain bearish on Moderna. The trend is in place as Monday failed to break above $259, so we remain with lower lows and lower highs. $259 is the pivot for the short term. $188.41 is the first target with $200 a big psychological level along the way. There is a pattern here: declining Relative Strength Index (RSI), declining Moving Average Convergence Divergence (MACD) and declining stock price. We have a volume gap from $200 until $180. There is more downside in our view unless MRNA shares close above $259.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD edges lower toward 1.0700 post-US PCE
EUR/USD stays under modest bearish pressure but manages to hold above 1.0700 in the American session on Friday. The US Dollar (USD) gathers strength against its rivals after the stronger-than-forecast PCE inflation data, not allowing the pair to gain traction.
GBP/USD retreats to 1.2500 on renewed USD strength
GBP/USD lost its traction and turned negative on the day near 1.2500. Following the stronger-than-expected PCE inflation readings from the US, the USD stays resilient and makes it difficult for the pair to gather recovery momentum.
Gold struggles to hold above $2,350 following US inflation
Gold turned south and declined toward $2,340, erasing a large portion of its daily gains, as the USD benefited from PCE inflation data. The benchmark 10-year US yield, however, stays in negative territory and helps XAU/USD limit its losses.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
Week ahead – Hawkish risk as Fed and NFP on tap, Eurozone data eyed too
Fed meets on Wednesday as US inflation stays elevated. Will Friday’s jobs report bring relief or more angst for the markets? Eurozone flash GDP and CPI numbers in focus for the Euro.